The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 340:1439 May 6, 1999 Number 18
NextNext

Long-Acting Gonadotropin-Releasing Hormone Implant to Maintain Medical Castration for Two Years in Men with Prostate Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by The International Study of Unruptured Intracranial Aneurysms Investigators
-PubMed Citation
To the Editor: Medical castration with long-acting gonadotropin-releasing hormone agonists is an effective therapy for men with metastatic prostate cancer.1,2 Initially, these agonists had to be given daily, but depot preparations that can be administered at intervals of one to three months are now available.3,4 We describe here the response to a longer-acting implant releasing the gonadotropin-releasing hormone agonist histrelin (Hydron, Hydro Med Sciences) in men with prostate cancer.

We treated 13 men 65 to 88 years of age who had prostate cancer that extended beyond the prostate capsule with 50 mg of the gonadotropin-releasing hormone agonist histrelin, administered with . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.